Nevertheless, we have clearly demonstrated that characteristic features of asthmatic inflammation developed only in animals that received particulates at the same time as respiratory sensitization, and were then chronically challenged with allergen.
We found that characteristic features of asthmatic inflammation developed only in animals that received particulates at the same time as respiratory sensitization, and were then chronically challenged with allergen.
Only animals that received particulates at the same time as respiratory sensitization and were then chronically challenged, i.e. the PM/OVA group, developed features characteristic of asthmatic inflammation.
They found that characteristic features of asthmatic inflammation developed only in weanling mice that received particulates at the same time as respiratory sensitization and were then chronically challenged with allergen.
While slow granular flows have been an area of active research in recent years, heat transfer in flowing particulate systems has received relatively little attention.
Continuous particulate blending has received much attention in the recent decade as it provides a more economical and efficient alternative over batch blending for large scale manufacturing.
Control groups included mice that were exposed to particulate matter but were not sensitized or challenged (PM/Nil), mice that did not receive particulates but were sensitized and challenged (Sham/OVA), and naïve mice.
We compared animals that were treated with particulate matter followed by OVA sensitization and challenge (PM/OVA) with mice that were exposed to particulate matter but were not sensitized or challenged (PM/Nil), mice that did not receive particulates but were sensitized and challenged (Sham/OVA), and naïve mice.
In particular, fine particulate matter (PM) has received increasing attention from scientists, governmental agencies, and the public due to its adverse impacts on human health.
Each patient received a particulate cancellous allograft (500 to 800 μm, RegenerOss, BioMet 3i), and then, the grafted defect area was covered with a bioresorbable matrix membrane (Sunstar, Suisse SA, Etoy, Switzerland).
